Therapeutic effect of fenofibrate for non-alcoholic steatohepatitis in mouse models is dependent on regime design

Background: Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver diseases. In most cases, NAFLD progresses from benign steatosis to steatohepatitis (NASH), and then to cirrhosis. No treatment is currently approved for NAFLD/NASH in the clinic. Fenofibrate (FENO) has been c...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xinxue, Luo, Jia, Lu, Zhuoheng, Fang, Shenzhe, Sun, Mengxia, Luo, Wenjing, Shen, Jianwei, Liu, Aiming, Ye, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213340/
https://www.ncbi.nlm.nih.gov/pubmed/37251331
http://dx.doi.org/10.3389/fphar.2023.1190458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213340/
https://www.ncbi.nlm.nih.gov/pubmed/37251331
http://dx.doi.org/10.3389/fphar.2023.1190458

Ejemplares similares